Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the publication of two new peer-reviewed articles detailing nonclinical data supporting the therapeutic potential of its investigational frataxin replacement …
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data Read More